Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposing Ivermectin for PKDL Treatment
NCT06251739Phase 1Completed
- Sponsor
- icddr,b
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CHILD-IVITAB in Post kala-azar dermal leishmaniasis (PKDL) (2 arms), sponsored by icddr,b. Primary endpoints: Parasitological clearance at 12 months and Lesion Reduction at 12 months. Started Oct 2023; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT06251739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251739.